- Home
- ANNX vs LGI Comparison
ANNX vs LGI Comparison
Compare ANNX & LGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANNX
- LGI
- Stock Information
- Founded
- ANNX 2011
- LGI 2004
- Country
- ANNX United States
- LGI United States
- Employees
- ANNX N/A
- LGI N/A
- Industry
- ANNX Biotechnology: Pharmaceutical Preparations
- LGI
- Sector
- ANNX Health Care
- LGI
- Exchange
- ANNX Nasdaq
- LGI Nasdaq
- Market Cap
- ANNX 253.8M
- LGI 210.5M
- IPO Year
- ANNX 2020
- LGI N/A
- Fundamental
- Price
- ANNX $2.06
- LGI $17.78
- Analyst Decision
- ANNX Strong Buy
- LGI
- Analyst Count
- ANNX 5
- LGI 0
- Target Price
- ANNX $13.00
- LGI N/A
- AVG Volume (30 Days)
- ANNX 1.2M
- LGI 41.1K
- Earning Date
- ANNX 08-14-2025
- LGI 01-01-0001
- Dividend Yield
- ANNX N/A
- LGI 7.10%
- EPS Growth
- ANNX N/A
- LGI N/A
- EPS
- ANNX N/A
- LGI N/A
- Revenue
- ANNX N/A
- LGI N/A
- Revenue This Year
- ANNX N/A
- LGI N/A
- Revenue Next Year
- ANNX N/A
- LGI N/A
- P/E Ratio
- ANNX N/A
- LGI N/A
- Revenue Growth
- ANNX N/A
- LGI N/A
- 52 Week Low
- ANNX $1.29
- LGI $12.66
- 52 Week High
- ANNX $7.85
- LGI $16.68
- Technical
- Relative Strength Index (RSI)
- ANNX 38.44
- LGI 72.46
- Support Level
- ANNX $2.06
- LGI $17.52
- Resistance Level
- ANNX $2.36
- LGI $17.61
- Average True Range (ATR)
- ANNX 0.17
- LGI 0.19
- MACD
- ANNX -0.03
- LGI 0.02
- Stochastic Oscillator
- ANNX 1.52
- LGI 96.30
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
About LGI Lazard Global Total Return and Income Fund
Lazard Global Total Return & Inc Fd Inc is a United States-based diversified, closed-end management investment company. Its investment objective is total return consisting of capital appreciation and income. The fund's portfolio of investments consists of different sector investments such as consumer staples, financials, consumer discretionary, healthcare, materials, sovereign debt and others.